Johnson & Johnson’s (JNJ) new depression drug off to a ‘very, very strong start’

NYSE: JNJ | Johnson & Johnson Common Stock News, Ratings, and Charts

JNJ – Up to 800 treatment centers are certified to administer Johnson & Johnson’s Spravato.

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Up to 800 health centers have been approved to administer Johnson & Johnson’s new ketamine-like depression drug, which was cleared for sale last month, and patients are already using it, the company said Tuesday.

Spravato, or esketamine, won federal approval March 5 for treatment-resistant depression. It’s similar to ketamine, a sedative known as the club drug “Special K” that’s increasingly being studied and used to treat depression.

Spravato’s side effects include sedation and dissociation. It also carries the potential risk of misuse and abuse. Acknowledging these factors, the FDA stipulated Spravato must be administered in a medically supervised health-care setting where patients are monitored. Pharmacies, doctor’s offices and clinics also need to be certified.

In a little more than a month, J&J has certified up to 800 sites, putting the company “well on track” with its plans for the year, Jennifer Taubert, executive vice president of pharmaceuticals, told analysts on a call Tuesday discussing first-quarter earnings results. She said a number of patients have received their first dose, with some receiving multiple doses.

“So we believe that we’re off to a very, very strong start with Spravato, and that it is going to be an important growth driver for us,” she said.


Johnson & Johnson shares were trading at $139.24 per share on Tuesday afternoon, up $2.72 (+1.99%). Year-to-date, Johnson & Johnson (JNJ - Get Rating) has gained 8.61%, versus a 16.68% rise in the benchmark S&P 500 index during the same period.

Johnson & Johnson (JNJ - Get Rating) currently has a StockNews.com POWR Rating of B (Buy), and is ranked #14 of 201 stocks in the Medical – Pharmaceuticals category.


This article is brought to you courtesy of CNBC.

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Top Stories on StockNews.com

NASDAQ: MLCO | Melco Resorts & Entertainment Limited News, Ratings, and Charts

5 Perfect Stocks?

This stock search started with over 8,000 and ended with only 5 stocks that combine the best of all these worlds.
NYSE: FSM | Fortuna Silver Mines Inc Ordinary Shares (Canada) News, Ratings, and Charts

Best & Worst Performing Stock Industries for July 17, 2019

Led by ticker FSM, "Miners - Silver" was our best performing stock industry of the day, with a 7.99% gain.
: GHSI | Guardion Health Sciences, Inc. News, Ratings, and Charts

Best & Worst Performing Small Cap Stocks for July 17, 2019

GHSI leads the way today as the best performing small cap stock, closing up 93.75%.
NASDAQ: PAAS | Pan American Silver Corp. News, Ratings, and Charts

Best & Worst Performing Mid Cap Stocks for July 17, 2019

PAAS leads the way today as the best performing mid cap stock, closing up 6.78%.
NYSE: ABT | Abbott Laboratories Common Stock News, Ratings, and Charts

Best & Worst Performing Mega Cap Stocks for July 17, 2019

ABT leads the way today as the best performing mega cap stock, closing up 3.13%.

Read More Stories


More Johnson & Johnson Common Stock (JNJ) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All JNJ News
Page generated in 1.04 seconds.